Pages that link to "Q34570396"
Jump to navigation
Jump to search
The following pages link to Denosumab in men receiving androgen-deprivation therapy for prostate cancer (Q34570396):
Displaying 50 items.
- Bisphosphonates for preventing and treating osteoporosis in men (Q24197612) (← links)
- Central control of fever and female body temperature by RANKL/RANK (Q24321735) (← links)
- Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review (Q24597422) (← links)
- Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality (Q24623768) (← links)
- The role of RANK-ligand inhibition in cancer: the story of denosumab (Q24633284) (← links)
- Opportunities to maximize value with integrated palliative care (Q26748634) (← links)
- Bone Metastasis from Renal Cell Carcinoma (Q26747493) (← links)
- Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer (Q26747782) (← links)
- Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer (Q26752785) (← links)
- Managing breast cancer in younger women: challenges and solutions (Q26771184) (← links)
- Prevention and treatment of bone fragility in cancer patient (Q26775765) (← links)
- Male Osteoporosis in the Elderly (Q26784352) (← links)
- Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients (Q26824762) (← links)
- New drugs for prostate cancer (Q26827515) (← links)
- Management of patients with biochemical recurrence after local therapy for prostate cancer (Q26849220) (← links)
- Nuclear receptors in bone physiology and diseases (Q26853017) (← links)
- Targeting bone physiology for the treatment of metastatic prostate cancer (Q26863249) (← links)
- Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences (Q26863493) (← links)
- Treatment of primary osteoporosis in men (Q26991748) (← links)
- Screening, diagnosis and treatment of osteoporosis: a brief review (Q26996726) (← links)
- Management of endocrine disease: Secondary osteoporosis: pathophysiology and management (Q26998249) (← links)
- Denosumab for the treatment of osteoporosis (Q27009275) (← links)
- Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer (Q27021268) (← links)
- Recent progress in pharmaceutical therapies for castration-resistant prostate cancer (Q27022567) (← links)
- Increasing options for the treatment of osteoporosis (Q28254516) (← links)
- Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab (Q28265584) (← links)
- 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary (Q28295416) (← links)
- RANKL/RANK-beyond bones (Q28308042) (← links)
- Mechanisms of action of therapeutic antibodies for cancer (Q28385366) (← links)
- Recent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short? (Q28552191) (← links)
- Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club. (Q30235173) (← links)
- Radium-223 dichloride in clinical practice: a review. (Q30251496) (← links)
- Food Fortification and Supplement Use-Are There Health Implications? (Q30252188) (← links)
- Role of denosumab in prostate cancer (Q30455154) (← links)
- Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases (Q33441667) (← links)
- Next generation of antibody therapy for cancer (Q33579636) (← links)
- Future of bisphosphonates and denosumab for men with advanced prostate cancer (Q33583525) (← links)
- Update in male osteoporosis (Q33586703) (← links)
- Recent advances in bone-targeted therapies of metastatic prostate cancer (Q33703763) (← links)
- Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options (Q33754036) (← links)
- Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer (Q33789201) (← links)
- Bone-targeting agents in prostate cancer (Q33864723) (← links)
- Leveraging human genetics to develop future therapeutic strategies in rheumatoid arthritis (Q33888733) (← links)
- The best of both worlds - managing the cancer, saving the bone (Q33920055) (← links)
- Lung cancer presenting as acrometastasis to the finger: a case report (Q33943078) (← links)
- Emerging treatment options for patients with castration‐resistant prostate cancer (Q33958519) (← links)
- Bone health and prostate cancer (Q33977536) (← links)
- Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer (Q33978286) (← links)
- Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer (Q34023510) (← links)
- Future directions of bone-targeted therapy for metastatic breast cancer (Q34023727) (← links)